RPL554
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Overview
RPL554 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
RPL554 clinical trials
Explore related
Medical disclaimer. This page summarizes research about RPL554 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.